| Influence of tumour micro-environment heterogeneity on therapeutic response MR Junttila, FJ De Sauvage Nature 501 (7467), 346-354, 2013 | 2747 | 2013 |
| Phosphatase‐mediated crosstalk between MAPK signaling pathways in the regulation of cell survival MR Junttila, SP Li, J Westermarck The FASEB Journal 22 (4), 954-965, 2008 | 1008 | 2008 |
| CIP2A inhibits PP2A in human malignancies MR Junttila, P Puustinen, M Niemelä, R Ahola, H Arnold, T Böttzauw, ... Cell 130 (1), 51-62, 2007 | 749 | 2007 |
| Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15+ Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy CX Dominguez, S Müller, S Keerthivasan, H Koeppen, J Hung, S Gierke, ... Cancer discovery 10 (2), 232-253, 2020 | 565 | 2020 |
| Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors DO Croci, JP Cerliani, T Dalotto-Moreno, SP Méndez-Huergo, ... Cell 156 (4), 744-758, 2014 | 548 | 2014 |
| Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer DVT Catenacci, MR Junttila, T Karrison, N Bahary, MN Horiba, SR Nattam, ... Journal of Clinical Oncology 33 (36), 4284-4292, 2015 | 519 | 2015 |
| Distinct thresholds govern Myc's biological output in vivo DJ Murphy, MR Junttila, L Pouyet, A Karnezis, K Shchors, DA Bui, ... Cancer cell 14 (6), 447-457, 2008 | 509 | 2008 |
| p53—a Jack of all trades but master of none MR Junttila, GI Evan Nature reviews cancer 9 (11), 821-829, 2009 | 507 | 2009 |
| Translational value of mouse models in oncology drug development SE Gould, MR Junttila, FJ de Sauvage Nature medicine 21 (5), 431-439, 2015 | 319 | 2015 |
| Selective activation of p53-mediated tumour suppression in high-grade tumours MR Junttila, AN Karnezis, D Garcia, F Madriles, RM Kortlever, F Rostker, ... Nature 468 (7323), 567-571, 2010 | 274 | 2010 |
| MYC-dependent regulation and prognostic role of CIP2A in gastric cancer A Khanna, C Böckelman, A Hemmes, MR Junttila, JP Wiksten, M Lundin, ... JNCI: Journal of the National Cancer Institute 101 (11), 793-805, 2009 | 268 | 2009 |
| Mechanisms of MYC stabilization in human malignancies MR Junttila, J Westermarck Cell cycle 7 (5), 592-596, 2008 | 224 | 2008 |
| Single‐step Strep‐tag® purification for the isolation and identification of protein complexes from mammalian cells MR Junttila, S Saarinen, T Schmidt, J Kast, J Westermarck Proteomics 5 (5), 1199-1203, 2005 | 194 | 2005 |
| p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells MR Junttila, R Ala-Aho, T Jokilehto, J Peltonen, M Kallajoki, R Grenman, ... Oncogene 26 (36), 5267-5279, 2007 | 177 | 2007 |
| Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer MR Junttila, W Mao, X Wang, BE Wang, T Pham, J Flygare, SF Yu, S Yee, ... Science translational medicine 7 (314), 314ra186-314ra186, 2015 | 168 | 2015 |
| Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells TT Junttila, J Li, J Johnston, M Hristopoulos, R Clark, D Ellerman, ... Cancer research 74 (19), 5561-5571, 2014 | 163 | 2014 |
| Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1 A Laine, H Sihto, C Come, MT Rosenfeldt, A Zwolinska, M Niemelä, ... Cancer discovery 3 (2), 182-197, 2013 | 157 | 2013 |
| A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types MC Wagle, D Kirouac, C Klijn, B Liu, S Mahajan, M Junttila, J Moffat, ... NPJ precision oncology 2 (1), 7, 2018 | 145 | 2018 |
| CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity J Li, R Piskol, R Ybarra, YJJ Chen, J Li, D Slaga, M Hristopoulos, R Clark, ... Science translational medicine 11 (508), eaax8861, 2019 | 142 | 2019 |
| p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1, 2 SP Li, MR Junttila, J Han, VM Kähäri, J Westermarck Cancer research 63 (13), 3473-3477, 2003 | 129 | 2003 |
